Initial Ph II 2b Results of Elios' Personalized Cancer Vaccine for the Treatment of Melanoma Look Promising

Initial Ph II 2b Results of Elios' Personalized Cancer Vaccine for the Treatment of Melanoma Look Promising

Source: 
CP Wire
snippet: 

Elios Therapeutics, a biopharmaceutical company developing particle-delivered, dendritic cell vaccines in the oncology arena, today presented initial open-label results from the ongoing Phase 2b clinical trial of the TLPLDC (tumor lysate, particle-loaded, dendritic cell) vaccine in patients with stage III and IV (resected) melanoma.